EGFR and cancer: For instance, gefitinib (Iressa®) and erlotinib (Tarceva®) are 4-amino quinazoline derivatives that have been shown to exert their anti-cancer activity through the inhibition of epidermal growth factor receptor (EGFR) [28,29].